A new trading day began on Monday, with Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) stock price up 3.20% from the previous day of trading, before settling in for the closing price of $11.57. CNTA’s price has ranged from $7.75 to $19.09 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -25.00% over the past five years. Meanwhile, its annual earnings per share averaged 29.13%. With a float of $84.29 million, this company’s outstanding shares have now reached $132.63 million.
Let’s look at the performance matrix of the company that is accounted for 77 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Centessa Pharmaceuticals plc ADR (CNTA) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Centessa Pharmaceuticals plc ADR is 36.45%, while institutional ownership is 54.85%. The most recent insider transaction that took place on Mar 25 ’25, was worth 163,386. In this transaction Chief Business Officer of this company sold 10,000 shares at a rate of $16.34, taking the stock ownership to the 134,021 shares. Before that another transaction happened on Mar 25 ’25, when Company’s Officer proposed sale 10,000 for $16.53, making the entire transaction worth $165,300.
Centessa Pharmaceuticals plc ADR (CNTA) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 29.13% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 6.48% during the next five years compared to -210.04% drop over the previous five years of trading.
Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) Trading Performance Indicators
Here are Centessa Pharmaceuticals plc ADR’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 9.25.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.99, a number that is poised to hit -0.34 in the next quarter and is forecasted to reach -1.55 in one year’s time.
Technical Analysis of Centessa Pharmaceuticals plc ADR (CNTA)
Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) saw its 5-day average volume 1.42 million, a positive change from its year-to-date volume of 0.96 million. As of the previous 9 days, the stock’s Stochastic %D was 41.60%. Additionally, its Average True Range was 1.25.
During the past 100 days, Centessa Pharmaceuticals plc ADR’s (CNTA) raw stochastic average was set at 24.66%, which indicates a significant decrease from 39.66% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 84.64% in the past 14 days, which was higher than the 64.53% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $15.53, while its 200-day Moving Average is $14.82. Nevertheless, the first resistance level for the watch stands at $12.22 in the near term. At $12.50, the stock is likely to face the second major resistance level. The third major resistance level sits at $12.86. If the price goes on to break the first support level at $11.58, it is likely to go to the next support level at $11.22. The third support level lies at $10.94 if the price breaches the second support level.
Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) Key Stats
With a market capitalization of 1.58 billion, the company has a total of 133,184K Shares Outstanding. Currently, annual sales are 0 K while annual income is -235,760 K. The company’s previous quarter sales were 0 K while its latest quarter income was -111,330 K.
